Stay updated on Pembrolizumab & Blinatumomab in ALL Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Blinatumomab in ALL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Blinatumomab in ALL Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the pembrolizumab and blinatumomab study is displayed with its study details, including that it is active but no longer recruiting participants.
    Difference
    55%
    Check dated 2026-11-09T03:50:42.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The site revision label changes from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T02:46:39.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    A site-wide banner announces the NIH transition to using “Super Intelligence” in place of “Artificial Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-26T04:14:46.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-19T05:22:08.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page remains a 403 Forbidden error, with the footer showing a newer site revision number.
    Difference
    0.2%
    Check dated 2026-10-12T03:14:27.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The study record page now displays a 403 Forbidden error, preventing viewing the NCT03512405 study details and related ClinicalTrials.gov content.
    Difference
    20%
    Check dated 2026-09-21T00:42:54.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Blinatumomab in ALL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Blinatumomab in ALL Clinical Trial page.